Clinical trials in Fuenlabrada – page 4

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

Study Comparing Trelegy with LABA-LAMA Drug Combination for Improving COPD Control in High-Risk Patients

Study on the Effectiveness and Safety of Sodium Cromoglicate for Treating Fatigue in Multiple Sclerosis Patients

Study on the Effectiveness and Safety of Sodium Cromoglicate for Treating Fatigue in Multiple Sclerosis Patients

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease

Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease